Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dihexazin is a small molecule active pharmaceutical ingredient (API) developed and manufactured by Laboratorios Juste (Grupo Juste), a Spanish pharmaceutical company specializing in radiology and contrast media. It is classified as a contrast media agent intended for use in diagnostic imaging applications. The compound has a molecular formula of C50H52N3O6P and a molecular weight of approximately 821.94. As an API in Grupo Juste's portfolio, it is part of their established line of specialty chemicals for the diagnostic imaging market. While its specific clinical applications and detailed mechanism of action are not widely publicized, it is listed as an approved product within the company's chemical and pharmaceutical ingredient offerings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dihexazin.